Amgen Inc. is an American multinational biopharmaceutical company headquartered in Thousand Oaks, California. Founded in 1980 as Applied Molecular Genetics Inc., it pioneered the use of recombinant DNA technology to develop biologic medicines.
The company discovers, develops, manufactures, and markets human therapeutics for serious illnesses, including cancer, cardiovascular disease, osteoporosis, inflammatory conditions, and rare diseases. Key products include Prolia and Xgeva (denosumab) for bone diseases, Enbrel (etanercept) for autoimmune disorders, Repatha (evolocumab) for hyperlipidemia, Otezla (apremilast) for psoriasis, Tepezza (teprotumumab) for Graves' ophthalmopathy, Kyprolis (carfilzomib) for multiple myeloma, and others such as Aranesp, Neulasta, and Nplate.
Amgen operates in approximately 100 countries with manufacturing facilities in the US, Puerto Rico, Ireland, the Netherlands, and Singapore. It is publicly traded on Nasdaq (AMGN) and ranks among the largest biomedical companies by revenue.
Phase 3 trial showed rapid, sustained reduction in systemic disease activity in moderate-to-severe Sjögren's disease with manageable safety signals.
Tarlatamab (IMDELLTRA) plus durvalumab showed statistically significant OS, PFS and ORR benefits versus durvalumab alone in Phase 3 DeLLphi‑305 for first‑line maintenance ES‑SCLC.
Pre‑specified VESALIUS‑CV analysis shows evolocumab plus background therapy lowers deaths and major CV events in high‑risk adults without prior MI/stroke.
Phase 3 CROSSING shows histologic remission and improved dysphagia at week 24 with benefits sustained through week 52 in symptomatic, uncontrolled eosinophilic esophagitis.
VESALIUS‑CV subgroup shows evolocumab lowers first major cardiovascular events and LDL‑C; real‑world GLP‑1 persistence is low, curbing potential benefits.
EU marketing authorisation for tarlatamab as monotherapy for extensive‑stage small cell lung cancer after progression on platinum‑based chemo; Phase 3 showed survival gain.
Successor returns July 1 as EVP and assumes CFO duties Sept 1; outgoing CFO stays through Jan 2027 to aid transition. Successor has 30+ yrs finance leadership, ex‑CFO at Galderma, Shire, Sulzer.
Expands Puerto Rico biologics facility to boost U.S. production, deploy next‑gen technologies, support workforce development and construction jobs, and strengthen medicine supply‑chain resilience
